Patients receiving the combination had the same treatment success rate as others treated with infliximab alone in a 50-week, placebo-controlled trial, reported Brian Feagan, M.D., of the Robarts Research Institute in London, Ontario, at Digestive Disease Week.
If further research backs up this finding then there'll be a lot of happy patients who'll be able to reduce the number of injections they need to take. In addition, fewer medications should lead to fewer side-effects.